In the first biopharma IPO in Europe this year, the French drug delivery company Adocia SAS has raised €25 million ($32.7 million) on NYSE Euronext Paris, in an offering that was oversubscribed.
The listing comes over nine months since Europe’s last biopharma IPO, that of dermatology-focused Moberg Pharma AB in May...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?